To the Shareholders of
We welcome this opportunity to provide our shareholders with a comprehensive picture of Love's efforts in building upon its existing portfolio and establishing its future strategic imperatives. Building upon LOVE's existing product portfolio, which is primarily over the counter, the Company's strategic imperative is aimed at positioning LOVE as a leader in the area of addiction treatment and recovery, within the pharmaceutical space.
LOVE is actively working to identify and assess biotechnology and pharmaceutical solutions to address addiction, with intent to grow its Pharmaceutical presence in underserved addiction treatment market.
Love Pharma Advancements
The partnership with researchers at
This research initiative aligns with key principles in
According to the
There are currently no FDA approved medications for CUD3
Current treatments, such as cognitive behavioral therapy, fail to maintain cannabis abstinence in patients4
The
We are looking forward to officially kicking-off our research initiative with the university this coming Fall and updating our shareholder community as we achieve milestones (for which there is no guarantee). Assuming our relationship with the researchers university is successful, it will allow the company to further develop its bond with the world-renowned institution and advance further clinical research initiatives.
Bloom & Auralief
Bloom was developed in one of the world's leading bioscience laboratories, BLOOM is a topical clitoral stimulation gel that enhances blood circulation, improving lubrication and heightening sensations.
Auralief is a patent pending, fast-acting oral strip that discreetly delivers 20 mgs of CBD when dissolved under the tongue. With effects in as little as 15 minutes, these paper-thin strips offer a user-friendly method of delivering the benefits of CBD to provide temporary relief from pain, anxiety, stress, and inflammation.
Chief Operating Officer,
Initial product inventory is produced and ready for sale
E-commerce platforms have been completed and in the process of being activated
B2C sales are scheduled to commence in the coming weeks, pending final platform testing
The Company's marketing plan is initially focused upon B2C, followed by the addition of B2B clients where larger sales volume anticipated long term
Logistically, LOVE has established a drop ship warehouse for fulfillment, delivering operational efficiencies and fixed shipping costs per unit
LOVE's online shop is in final stages of development, and once complete the robust sales platform will deliver a scalable, plug and play sales solution for the Company's existing, and future product portfolio
Bloom: https://bloomarousal.com
Auralief: https://auraliefstrips.com
Doc Hygiene Acquisition
The recently announced acquisition of Doc Hygiene (https://dochygiene.com/), delivers an established brand with strong IP, and a comprehensive e-commerce platform that LOVE will be building upon to significantly expand the Company's online sales.
LOVE's management team is of the view that the Acquisition is accretive, building value for shareholders by combining Doc Hygiene's trusted line of personal sanitizer products with LOVE's growing line of science-backed nutraceutical and psychedelic products.
Financing and Market Update
In this time of challenging markets, LOVE has been extraordinarily successful in raising over
LOVE is in advanced stages in the process to attain an OTC listing in the
LOVE's existing over the counter product portfolio is at the leading edge of innovation and advancing rapidly. Moving forward, the Company will build on its assets and newly acquired e-commerce platforms, leveraging the knowledge base being developed through its research partners at
About
With a focus on the global sexual Health and Wellness markets,
Contact:
Investor
Telephone: 1 (604) 343-2977
E-mail: investors@love-pharma.com
WEB: www.love-pharma.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Certain statements contained in this release may constitute 'forward-looking statements' or 'forward-looking information' (collectively 'forward-looking information') as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words 'could', 'intend', 'expect', 'believe', 'will', 'projected', 'estimated', 'anticipates' and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, financing, and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
(C) 2022 Electronic News Publishing, source